Jasia Mahdi, MD

Dr. Jasia Mahdi is a pediatric neurologist and neuro-oncologist with a specific focus in neuro-immuno-oncology. At Baylor College of Medicine and Texas Children's Hospital, Dr. Mahdi serves as the Director of Neuro-oncology for the Division of Pediatric Neurology and is the neurologist for the Pediatric Brain Tumor Program where she manages oncology patients with neurologic problems. She was previously an attending physician at Stanford University from 2022 to 2024, where she developed an expertise in neuro-immuno-oncology by acting as the co-principal investigator on a phase I clinical trial utilizing GD2-CAR T therapy for the treatment of diffuse midline gliomas/diffuse intrinsic pontine gliomas and taking care of patients receiving immunotherapy for CNS tumors. At Baylor College of Medicine and Texas Children’s hospital, she helps conduct clinical trials utilizing immunotherapy for the treatment of CNS tumors, with a specific research focus on defining, assessing, and treating the neurotoxicities that arise secondary to treatment.

Clinical Interests

CNS tumors, immunotherapy, neurotoxicities

Education

Organizations

Board Certification

American Board of Psychiatry and Neurology, Special Certificate in Child Neurology

United Council for Neurologic Subspecialties, Neuro-Oncology

Honors and awards

2011-2015

The Leonard Tow Humanism in Medicine Award, the Arnold P. Gold Foundation

2011

Phi Beta Kappa

* Texas Children’s Hospital physicians’ licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician’s office and were not verified by Texas Children’s Hospital.

Mahdi J, Dietrich J, Straathof K, Roddie C, Scott BJ, Davidson TB, Prolo LM, Bachelor TT, Campen CJ, Davis KL, Gust J, Lim M, Majzner RG, Park JR, Partap S, Ramakrishna S, Richards R, Schultz L, Vitanza NA, Wang LD, Mackall CL, Monje M. Tumor Inflammation-Associated Neurotoxicity (TIAN). Nature Medicine, 2023 Apr;29(4):803-810. doi: 10.1038/s41591-023-02276-w. Epub 2023 Apr 6. PMID: 37024595

Mahdi J, Bach A, Smith AE, Tomko SR, Fields ME, Griffith JL, Morris SM, Guerriero RM, Noetzel MJ, Guilliams KP, Agner SC. Stroke Mimics are Not Benign in Immunocompromised Children. Stroke, 2022 Jul 18 :101161STROKEAHA122039311. PMID: 35862209

Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM, Richards RM, Jiang L, Barsan V, Mancusi R, Geraghty AC, Good Z, Mochizuki AY, Gillespie SM, Toland AMS, Mahdi J*, Reschke A, Nie EH, Chau IJ, Rotiroti MC, Mount CW, Baggott C, Mavroukakis S, Egeler E, Moon J, Erickson C, Green S, Kunicki M, Fujimoto M, Ehlinger Z, Reynolds W, Kurra S, Warren KE, Prabhu S, Vogel H, Rasmussen L, Cornell TT, Partap S, Fisher PG, Campen CJ, Filbin MG, Grant G, Sahaf B, Davis KL, Feldman SA, Mackall CL, Monje M. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature, 2022 Mar; 603(7903):934-941. PMID: 35130560

Mahdi J, Goyal MS, Griffith J, Morris SM, Gutmann DH. Non-optic Pathway Tumors in Children with Neurofibromatosis type 1. Neurology, 2020 Aug 25; 95(8):e1052-e1059. PMID: 32300062

Mahdi J, Shah AC, Sato A, Morris SM, McKinstry RC, Listernick R, Packer RJ, Fisher MJ, Gutmann DH. A Multi-Institutional Study of Brainstem Gliomas in Individuals with Neurofibromatosis type 1. Neurology, 2017 Apr 18; 88(16): 1584-1589. PMID: 28330960

Griffith JL, Morris SM, Mahdi J*, Goyal MS, Hershey T, Gutmann DH. Increased Prevalence of Brain Tumors Classified as T2 Hyperintensities in Neurofibromatosis 1. Neurology: Clinical Practice, 2018 Aug; 8(4): 283-291. PMID: 30140579

Ladner TR, Mahdi J*, Gindville MC, Gordon A, Harris ZL, Crossman K, Pruthi S, Abramo TJ, Jordan LC. Pediatric Acute Stroke Protocol Activation in a Children’s Hospital Emergency Department. Stroke, 2015 Aug; 46(8): 2328-3. PMID: 26138119